CareDx (NASDAQ:CDNA) has been given a $12.00 price objective by investment analysts at HC Wainwright in a research note issued on Friday. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 100.67% from the company’s previous close.
A number of other research firms have also recently weighed in on CDNA. ValuEngine cut shares of CareDx from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $8.65.
Shares of CareDx (CDNA) opened at $5.98 on Friday. CareDx has a 1 year low of $0.76 and a 1 year high of $7.98. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55. The stock has a market cap of $173.34, a price-to-earnings ratio of -3.30 and a beta of 0.72.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FNY Partners Fund LP purchased a new position in shares of CareDx during the 4th quarter valued at $102,000. Two Sigma Advisers LP purchased a new position in shares of CareDx during the 4th quarter valued at $105,000. Wells Fargo & Company MN lifted its stake in shares of CareDx by 1,360.6% during the 4th quarter. Wells Fargo & Company MN now owns 16,636 shares of the company’s stock valued at $122,000 after buying an additional 15,497 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of CareDx during the 4th quarter valued at $130,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CareDx during the 4th quarter valued at $134,000. Institutional investors own 52.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2018/03/23/hc-wainwright-reiterates-12-00-price-target-for-caredx-cdna.html.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.